β-amyloid and tau drive early Alzheimer’s disease decline while glucose hypometabolism drives late decline

Clinical trials focusing on therapeutic candidates that modify β-amyloid (Aβ) have repeatedly failed to treat Alzheimer’s disease (AD), suggesting that Aβ may not be the optimal target for treating AD. The evaluation of Aβ, tau, and neurodegenerative (A/T/N) biomarkers has been proposed for classify...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammond, Tyler C., Xing, Xin, Wang, Chris, Ma, David, Nho, Kwangsik, Crane, Paul K., Elahi, Fanny, Ziegler, David A., Liang, Gongbo, Cheng, Qiang, Yanckello, Lucille M., Jacobs, Nathan, Lin, Ai-Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338410/
https://www.ncbi.nlm.nih.gov/pubmed/32632135
http://dx.doi.org/10.1038/s42003-020-1079-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338410/
https://www.ncbi.nlm.nih.gov/pubmed/32632135
http://dx.doi.org/10.1038/s42003-020-1079-x

Ejemplares similares